Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Platinum-Sensitive Ovarian Cancer in First Relapse 1Pituitary Neoplasms 1Peritoneal Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 12Cisplatin 11Hyperthermic Intraperitoneal Chemotherapy 10Cytoreduction Surgical Procedures 9Oxaliplatin 8Fluorouracil 7Mitomycin 6Carboplatin 5Leucovorin 4Bevacizumab 4catumaxomab 3Doxorubicin 3Docetaxel 3sodium thiosulfate 2Indocyanine Green 2Drug Therapy 2Cetuximab 2volociximab 1vandetanib 1relacorilant 1pasireotide 1nilotinib 1farletuzumab 1epothilone B 1enzastaurin 1birinapant 1alvimopan 1Surgical Procedures, Operative 1Saline Waters 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Peritoneal Neoplasms × farletuzumab × Clear all
NCT00318370 2015-09-09

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Morphotek

Phase 2 Completed
58 enrolled 12 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡